1-12 of 12
Saad Usmani
Close
Sort by
Articles

Minimal Residual Disease Negativity in Multiple Myeloma: One Good Season Is Not Enough

Gunjan Shah, MD, MS, Saad Usmani, MD, MBA, FACP
Journal: The Hematologist
The Hematologist (2022) 19 (4)
https://doi.org/10.1182/hem.V19.4.2022411
Published: 2022
Articles

Deep OCEAN Dive

Santiago Thibaud, MD, Saad Usmani, MD, MBA, FACP
Journal: The Hematologist
The Hematologist (2022) 19 (3)
https://doi.org/10.1182/hem.V19.3.2022313
Published: 2022
Articles

Primary Plasma Cell Leukemia Re(de)fined

Carlyn Rose, Tan, MD, Saad Usmani, MD, MBA, FACP
Journal: The Hematologist
The Hematologist (2022) 19 (2)
https://doi.org/10.1182/hem.V19.2.2022210
Published: 2022
Articles

iStopMM: A Monumental Effort

Malin Hultcrantz, MD, PhD, Saad Usmani, MD, MBA, FACP
Journal: The Hematologist
The Hematologist (2022) 19 (1)
https://doi.org/10.1182/hem.V19.1.202217
Published: 2022
Articles

Daratumumab and Lenalidomide Maintenance Guided by Minimal Residual Disease in Multiple Myeloma

Binod Dhakal, MD, Saad Usmani, MD, MBA, FACP
Journal: The Hematologist
The Hematologist (2021) 18 (6)
https://doi.org/10.1182/hem.V18.6.202166
Published: 2021
Articles

The ANDROMEDA Study: Is Daratumumab Plus CyBorDex the New Standard of Care for Newly Diagnosed AL Amyloidosis?

Hamza Hashmi, MD, Saad Usmani, MD, MBA, FACP
Journal: The Hematologist
The Hematologist (2021) 18 (5)
https://doi.org/10.1182/hem.V18.5.202158
Published: 2021
Articles

Immune Therapies for Myeloma: The CARs Are Here but What's Next?

Sham Mailankody, MD, Saad Usmani, MD, MBA, FACP
Journal: The Hematologist
The Hematologist (2021) 18 (4)
https://doi.org/10.1182/hem.V18.4.2021413
Published: 2021
Articles

BOSTON Trial: Selinexor, Are We There Yet?

Samer Al Hadidi, MD, MS, FACP, Saad Usmani, MD, MBA, FACP
Journal: The Hematologist
The Hematologist (2021) 18 (3)
Published: 2021
Articles

Battle of the Proteasome Inhibitors: Which One Endured?

Saad Usmani, MD, MBA, FACP
Journal: The Hematologist
The Hematologist (2021) 18 (2)
Published: 2021
Articles

Mye-llennial Dilemma: What Are the Optimal Endpoints for Multiple Myeloma Clinical Trials?

Shebli Atrash, MD, Saad Usmani, MD
Journal: The Hematologist
The Hematologist (2020) 17 (4)
https://doi.org/10.1182/hem.V17.4.12884901897
Published: 2020
Articles

A Story About a River Named Indus

Saad Usmani, MD
Journal: The Hematologist
The Hematologist (2019) 16 (3)
https://doi.org/10.1182/hem.V16.3.9592
Published: 2019
Articles

59th ASH Annual Meeting Wrap-up: Hotlanta Freezes Over

Saad Usmani, MD
Journal: The Hematologist
The Hematologist (2018) 15 (1)
https://doi.org/10.1182/hem.V15.1.8180
Published: 2018